What is the best option for introducing intravenous immunoglobin to patients with chronic inflammatory demyelinating polyneuropathy (CIDP)? Researchers publishing in the Journal of the Neurological Sciences explored the question in a paper that looked at two options: intravenous (IVIG) or subcutaneous (SCIG) immunoglobin. Their study included a look at the research on the two. IVIG, which they noted can be delivered safely in a hospital setting, was a good option for induction and maintenance. In 2018, the FDA also approved SCIG for maintenance in patients with CIDP. Decisions about what option was best to use, they noted, should be discussed between patients and caregivers, and include factors such as pharmacokinetics, adverse event profiles, site of care/administration, dosing and frequency of administration, and patient preferences and goals, economics, and a variety of other factors. “The decision to use SCIG or IVIG is one that is best individualized to each patient’s disease characteristics, treatment goals, and lifestyle,” they wrote. “There is no ‘best’ method to determine which route of administration is optimal for every patient.”

 

This article was originally published here